<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04140591</url>
  </required_header>
  <id_info>
    <org_study_id>V106C-137</org_study_id>
    <nct_id>NCT04140591</nct_id>
  </id_info>
  <brief_title>Proton Pump Inhibitor Plus Propranolol Versus Proton Pump Inhibitor Alone on Peptic Ulcer Healing in Patients With Liver Cirrhosis</brief_title>
  <acronym>PU</acronym>
  <official_title>Proton Pump Inhibitor Plus Propranolol Versus Proton Pump Inhibitor Alone on Peptic Ulcer Healing in Patients With Liver Cirrhosis: a Randomized Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proton pump inhibitor plus propranolol versus proton pump inhibitor alone on peptic ulcer
      healing in patients with liver cirrhosis: a randomized trail
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Portal hypertension is responsible for the development of portosystemic collaterals. The
      hemodynamic alternations may result in mucosal and vascular changes along gastrointestinal
      (GI) tract as well. According to several epidemiological studies, cirrhotic patients are at a
      higher risk of developing peptic ulcers, delayed healing, and a higher frequency of ulcer
      recurrence. The death rate from peptic ulcer disease in cirrhotic patients has been reported
      to be five times higher than that of the general population. The exact mechanism remains
      incompletely understood, but may be related to impaired mucosal defense mechanisms.
      Aggressive factors such as Helicobacter pylori and gastric acid may not be the predominant
      etiology in such circumstances. Sarfeh et al. found gastric mucosa of portal hypertensive
      rats, compared with that of controls, has distinctive functional and histologic abnormalities
      that can explain its increased susceptibility to erosive injury. Auroux et al. found
      gastroduodenal ulcer was independently associated only with the severity of the hypertensive
      gastropathy in cirrhotics. Chen et al. found portal hypertension with a hepatic venous
      pressure gradient &gt; 12 mmHg may be an important factor contributing to the increased
      prevalence of gastric ulcer observed in patients with liver cirrhosis. Thereby, we presumed
      that clinically significant portal hypertension may play a role in development of peptic
      ulcer in cirrhotic patients. Lebrec et al. elucidated non-selective beta-blocker (NSBB) could
      significantly decrease portal pressure and lower the risk of GI bleeding in patients with
      cirrhosis. Kitano et al. found portal hypotensive treatment with NSBB, reduces
      ethanol-induced gastric mucosal damage in portal hypertensive rats and improves endoscopic
      signs of portal hypertensive gastropathy in cirrhosis patients. We designed a 2-year
      randomized trial to evaluate the effectiveness of proton pump inhibitor with or without
      propranolol on ulcer healing and the incidence of ulcer bleeding in patients with cirrhosis
      and peptic ulcers.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    1. Most patients with liver cirrhosis already use PPI and NSBB 2. 90 % Peptic ulcer size is
    smaller than 5cm
  </why_stopped>
  <start_date type="Actual">December 26, 2016</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing of peptic ulcer</measure>
    <time_frame>2 months</time_frame>
    <description>if propranolol can help cure peptic ulcer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding rate of peptic ulcer</measure>
    <time_frame>2 months</time_frame>
    <description>if propranolol can help decrease the rate of ulcer bleeding</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Peptic Ulcer</condition>
  <arm_group>
    <arm_group_label>Proton-pump inhibitor</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PPI: Pariet EC 20 mg/QDAC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol+Proton-pump inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propranolol:
Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate&gt;55 or systemic blood pressure&gt;90mmHg)
PPI: Pariet EC 20 mg/QDAC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proton-pump inhibitor</intervention_name>
    <description>PPI: Pariet EC 20mg/QDAC</description>
    <arm_group_label>Proton-pump inhibitor</arm_group_label>
    <other_name>Pariet EC</other_name>
    <other_name>PPI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol+Proton-pump inhibitor</intervention_name>
    <description>Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate&gt;55 or systemic blood pressure &gt;90mmHg) PPI: Pariet EC 20mg/QDAC</description>
    <arm_group_label>Propranolol+Proton-pump inhibitor</arm_group_label>
    <other_name>Inderal</other_name>
    <other_name>Cardolol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 20 and 85 years old

          -  Liver cirrhosis associated with esophageal varices or gastric varices

          -  Gastric ulcer or duodenal ulcer ,size bigger or egual than 0.5 cm

        Exclusion Criteria:

          -  Acute bleeding

          -  Steroid or NSAID user

          -  Pregnancy, or the patients with other terminal illness (such as other terminal
             cancers, heart failure, renal failure...)

          -  Propranolol contraindications (such as atrioventricular block, heart failure, chronic
             obstructive pulmonary disease, asthma, poorly controlled diabetes, severe peripheral
             arterial disease...)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Chih mchou@vghtpe.gov.tw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institutional Review Board, Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital, Taiwan</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei Veterans General Hospital, Taiwan</investigator_affiliation>
    <investigator_full_name>vghtpe user</investigator_full_name>
    <investigator_title>The Division of Gastroenterology &amp; Hepatology</investigator_title>
  </responsible_party>
  <keyword>Portal hypertension</keyword>
  <keyword>Peptic ulcer</keyword>
  <keyword>Non-selective beta-blocker</keyword>
  <keyword>Proton pump inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Peptic Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

